Palvella Therapeutics (PVLA) Operating Margin (2014 - 2024)
Palvella Therapeutics (PVLA) reported Operating Margin of 3318.87% for Q1 2024, down 251768.0% year-over-year from N/an in Q2 2023, and down 4276.34% on a QoQ basis from 75.84% in Q3 2023.
Palvella Therapeutics (PVLA) has 11 years of Operating Margin data on file, last reported at 3318.87% in Q1 2024.
- Quarterly Operating Margin fell 251768.0% year-over-year to 3318.87% in Q1 2024, while the trailing twelve-month figure through Sep 2024 was 23.41% (up 12236.0% YoY) and the FY2021 annual result came in at 185.51%, down 6983.0% from the prior year.
- Operating Margin retreated to 3318.87% in Q1 2024 per PVLA's latest filing, from 75.84% in the prior quarter.
- Across five years, Operating Margin topped out at 10.29% in Q2 2023 and bottomed at 4716.28% in Q3 2022.
- The 5-year median for Operating Margin is 355.54% (2022), against an average of 806.85%.
- The widest annual swing landed in 2022, when Operating Margin tumbled 403313 bps; it then jumped 464044 bps in 2023.
- Tracing PVLA's Operating Margin over 5 years: stood at 661.21% in 2020, then soared by 66 bps to 221.53% in 2021, then plunged by 2029 bps to 4716.28% in 2022, then jumped by 98 bps to 75.84% in 2023, then sank by 4276 bps to 3318.87% in 2024.
- Per Business Quant, the three latest PVLA Operating Margin figures stand at 3318.87% (Q1 2024), 75.84% (Q3 2023), and 10.29% (Q2 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -3,318.87% |
| Sep 30, 2023 | -75.84% |
| Jun 30, 2023 | 10.29% |
| Mar 31, 2023 | -801.19% |
| Sep 30, 2022 | -4,716.28% |
| Jun 30, 2022 | -355.54% |
| Mar 31, 2022 | -67.86% |
| Dec 31, 2021 | -221.53% |
| Sep 30, 2021 | -683.15% |
| Jun 30, 2021 | -659.88% |
| Mar 31, 2021 | -38.92% |
| Dec 31, 2020 | -661.21% |
| Sep 30, 2020 | -442.29% |
| Jun 30, 2020 | -41.39% |
| Mar 31, 2020 | -29.08% |
| Dec 31, 2019 | -43.52% |
| Sep 30, 2019 | -19.26% |
| Jun 30, 2019 | -229.37% |
| Mar 31, 2019 | -125.02% |
| Dec 31, 2018 | -2,108.00% |
| Sep 30, 2018 | -93.52% |
| Jun 30, 2018 | -19.19% |
| Mar 31, 2018 | -195.95% |
| Dec 31, 2017 | 35.74% |
| Sep 30, 2017 | -132.01% |
| Jun 30, 2017 | -425.85% |
| Mar 31, 2017 | -596.13% |
| Dec 31, 2016 | -234.91% |
| Sep 30, 2016 | -786.99% |
| Jun 30, 2016 | -540.19% |
| Mar 31, 2016 | -351.40% |
| Dec 31, 2015 | 606.08% |
| Sep 30, 2015 | -935.79% |
| Jun 30, 2015 | -2,205.66% |
| Mar 31, 2015 | -1,700.82% |
| Sep 30, 2014 | -9,832.80% |
| Jun 30, 2014 | -396.71% |